Lack of correlation between Treg quantification assays in inflammatory bowel disease patients

作者: Gunnar Brandhorst , Darinka Todorova Petrova , Sebastian Weigand , Christoph Eberle , Nicolas von Ahsen

DOI: 10.3748/WJG.V21.I11.3325

关键词: FOXP3BiologyPeripheral blood mononuclear cellFlow cytometryColitisReal-time polymerase chain reactionInflammatory bowel diseaseImmunologyCrohn's diseaseUlcerative colitis

摘要: AIM: To compare the number of regulatory T-cells (Tregs) measured by flow cytometry with those obtained using a real-time quantitative PCR (qPCR) method in patients suffering from inflammatory bowel disease (IBD). METHODS: Tregs percentages both and qPCR methods 35 adult IBD patients, 18 out them Crohn´s (CD) 17 ulcerative colitis (UC) were compared to each other as well scores on two activity questionnaires Harvey Bradshaw Index (HBI) for CD Simple Colitis Clinical Activity (SCCAI) UC patients. The Treg defined CD4+CD25highCD127lowFOXP3+ cells peripheral blood mononuclear cells, whereas determined FOXP3 promoter demethylation genomic DNA. RESULTS: We found an average 1.56% ± 0.78% cytometry, 1.07% 0.53% There no significant correlations between either or HBI SCCAI questionnaire respectively. In addition, there was correlation (r = -0.06, P 0.73; Spearman Rho). These data suggest that, Treg-related immune function clinical these did not accurately reflect actual activity. Until cause(s) differences are more clearly defined, results caution interpreting studies various disorders. CONCLUSION: produce equivalent measures percentage total studied which is consistent conclusion that subtypes equally detected assays.

参考文章(22)
Xiaoshun He, Song Guo Zheng, Maogen Chen, Maogen Chen, David Brand, Ya Liu, Xiaohong Lin, Zhiyong Guo, Advances in distinguishing natural from induced Foxp3+ regulatory T cells International Journal of Clinical and Experimental Pathology. ,vol. 6, pp. 116- 123 ,(2013)
Megan E. Himmel, Yu Yao, Paul C. Orban, Theodore S. Steiner, Megan K. Levings, Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers Immunology. ,vol. 136, pp. 115- 122 ,(2012) , 10.1111/J.1365-2567.2012.03572.X
Clare Baecher-Allan, Julia A. Brown, Gordon J. Freeman, David A. Hafler, CD4+CD25high Regulatory Cells in Human Peripheral Blood Journal of Immunology. ,vol. 167, pp. 1245- 1253 ,(2001) , 10.4049/JIMMUNOL.167.3.1245
Mary E. Brunkow, Eric W. Jeffery, Kathryn A. Hjerrild, Bryan Paeper, Lisa B. Clark, Sue-Ann Yasayko, J. Erby Wilkinson, David Galas, Steven F. Ziegler, Fred Ramsdell, Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genetics. ,vol. 27, pp. 68- 73 ,(2001) , 10.1038/83784
Frank Christian Schultze, Reiner Andag, Salamah Mohammad Alwahsh, Draga Toncheva, Svilen Maslyankov, Nikolay Yaramov, Nicolas von Ahsen, Gunnar Brandhorst, Philip D. Walson, Michael Oellerich, Darinka Todorova Petrova, FoxP3 demethylation is increased in human colorectal cancer and rat cholangiocarcinoma tissue Clinical Biochemistry. ,vol. 47, pp. 201- 205 ,(2014) , 10.1016/J.CLINBIOCHEM.2013.11.013
Warren Strober, Ivan Fuss, Peter Mannon, The fundamental basis of inflammatory bowel disease Journal of Clinical Investigation. ,vol. 117, pp. 514- 521 ,(2007) , 10.1172/JCI30587
Claus Dieter Dummer, Virna Nowotny Carpio, Luiz Felipe Santos Gonçalves, Roberto Ceratti Manfro, Francisco Veríssimo Veronese, FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transplant Immunology. ,vol. 26, pp. 1- 10 ,(2012) , 10.1016/J.TRIM.2011.08.009
Itay Shalev, Nazia Selzner, Wendy Shyu, David Grant, Gary Levy, Role of regulatory T cells in the promotion of transplant tolerance. Liver Transplantation. ,vol. 18, pp. 761- 770 ,(2012) , 10.1002/LT.23458
Jochen Maul, Martin Zeitz, Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations Langenbeck's Archives of Surgery. ,vol. 397, pp. 1- 10 ,(2012) , 10.1007/S00423-011-0789-4
G. Brandhorst, S. Weigand, C. Eberle, D. Raddatz, M. Karaus, M. Oellerich, P.D. Walson, CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity. Clinica Chimica Acta. ,vol. 421, pp. 31- 33 ,(2013) , 10.1016/J.CCA.2013.02.016